Claudio Carini, MD, PhD. FRCPath
Translational Medicine and Biomarkers
Claudio Carini MD, PhD, FRCPath, board certified in Internal Medicine, Respiratory Medicine, and Clinical Immunology, is an academic physician, and an experienced pharmaceutical executive. Dr. Carini has been involved in biomedical research for over 25 years. Currently, Dr. Carini is serving as “Global Clinical Immunology and Biomarkers Lead” at Pfizer being responsible of the Biosimilars portfolio Biomarkers strategy. Dr. Carini research interest in Translational Medicine covers several therapeutic areas, and focuses on early and late clinical translational models; biomarkers for decision making, Pharmacogenomics, Proteomics, clinical assays, and human bio bank. Dr. Claudio Carini served as Chief Medical Officer and Vice President at Fresenius Pharmaceuticals; Global Head of Translational Medicine and Head of The Biomarker Alliance at MDS Pharma; Global Head of Biomarkers at Hoffman La Roche, and Global Director and Therapeutic Area Head of Translational Medicine at Novartis. During these years, he successfully implemented the Translational Research to reduce the length and cost of clinical development. Prior to joint the pharmaceutical industry, Previously, Dr. Carini was faculty at the Johns Hopkins University and Harvard University.
Dr. Carini has over 200 publications in peer-reviewed journals, is invited speaker at national and international meetings, has been recipient of meritorious scientific research awards, is member of national and international societies, and serves as ad hoc reviewer for numerous scientific journals.
Dr Carini is serving in national and international scientific boards: NIH Biomarkers Consortium Immunology: Steering Committee. NIH Biomarkers Consortium “ Rheumatoid Arthritis RFP: Working Group. Medical Research Council (UK) Inflammation/ Immunology Initiative; Rheumatoid Arthritis Consortium: Steering Committee. Innovation Medicine Initiative, ABIRIS- European Union/EFPIA: Board of Directors. The PML Consortium: Board of Directors. The ISAC “Immuno-Safety Advisory Council: Board of Directors. The Generation Scotland Precision Medicine Initiative University of Scotland (UK): Board of Directors. The Immunogenicity Council: Board of Directors. The Grand Challenge Inflammation & Precision Medicine, Univ. of Glasgow: Board of Directors. The Kidney Biomarkers Initiative: Board of Directors.
On 15 September 2011, Biomarkers in Drug Development by Michael R. Bleavins, Claudio Carini, Mallé Jurima-Romet and Ramin Rahbari was “highly commended” at the British Medical Association Medical Book Awards.